Codexis, Inc.
NASDAQ:CDXSBiotechnology
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
Volume 1.47M
Average 1.15M
Dividends
Codexis, Inc. dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Codexis, Inc. compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
OmniAb, Inc. NASDAQ:OABI | $716.17M | 0.00% | $0.00 | 0.00% | 0.00% |
C4 Therapeutics, Inc. NASDAQ:CCCC | $362.43M | 0.00% | $0.00 | 0.00% | 0.07% |
Invivyd, Inc. NASDAQ:IVVD | $171.58M | 0.00% | $0.00 | 0.00% | 0.00% |
Protara Therapeutics, Inc. NASDAQ:TARA | $155.77M | 0.00% | $0.00 | 0.00% | 0.00% |
Innate Pharma S.A. NASDAQ:IPHA | $154.15M | 0.00% | $0.00 | 0.00% | 0.00% |
Armata Pharmaceuticals, Inc. AMEX:ARMP | $143.89M | 0.00% | $0.00 | 0.00% | 0.00% |
Insight Molecular Diagnostics Inc. NASDAQ:IMDX | $70.03M | 0.00% | $0.00 | 0.00% | 0.00% |
Rani Therapeutics Holdings, Inc. NASDAQ:RANI | $34.38M | 0.00% | $0.00 | 0.00% | 0.00% |
Sangamo Therapeutics, Inc. NASDAQ:SGMO | $30.66M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about CDXS's dividend, answered from reported figures.
Does CDXS stock pay dividends?
Codexis, Inc. (CDXS) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is CDXS's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.